PremiumThe FlyAkari Therapeutics appoints Gaslightwala as CEO Biotech Alert: Searches spiking for these stocks today Jazz Pharmaceuticals price target raised to $213 from $182 at BofA PremiumThe FlyJazz Pharmaceuticals upgraded to Buy from Neutral at UBS Jazz Pharmaceuticals price target raised to $230 from $220 at Truist Strategic Acquisition of Chimerix Enhances Jazz Pharmaceuticals’ Oncology Portfolio and Supports Buy Rating PremiumThe FlyJazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cash Jazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cash, or $935M Jazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cash 
